Melief, Sara M <br/><br/>
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.  [electronic resource] 

 -  Cancer immunology research  02 2017 
 - 170-179 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2326-6074 
<br/><br/><label>Standard No.: </label>10.1158/2326-6066.CIR-16-0288  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biomarkers<br/>Female<br/>Galectins--metabolism<br/>Humans<br/>Immunity<br/>Immunotherapy, Adoptive<br/>Macrophages--immunology<br/>Male<br/>Melanoma--immunology<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Survival Analysis<br/>T-Lymphocyte Subsets--immunology<br/>Treatment Outcome